You are here: Industry Insights > Tumor

News List

Rozlytrek Approved to Treat Tumors With NTRK Gene Fusion drugs
August 20, 2019
Rozlytrek (entrectinib), a kinase inhibitor, has received approval to treat adults and adolescents with cancer that carries the genetic defect neurotrophic tyrosine receptor kinase (NTRK) gene fusion and...
New Treatments Could Be Powerful Weapons Against Brain Tumors drugs
August 15, 2019
New therapies are showing real promise in fighting the type of brain cancer that claimed the lives of Sens. John McCain and Ted Kennedy, a pair of new clinical trials shows.
Turalio (Pexidartinib) Approved to Treat Tenosynovial Giant Cell Tumor drugs
August 06, 2019
Turalio (pexidartinib) capsules have been approved to treat adults with symptomatic tenosynovial giant cell tumor (TGCT)...
FDA approves first therapy for rare joint tumor drugs
August 05, 2019
The U.S. Food and Drug Administration granted approval to Turalio (pexidartinib) capsules for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT)...
FDA Approves Turalio (pexidartinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT) in Adults drugs
August 05, 2019
The U.S. Food and Drug Administration granted approval to Turalio (pexidartinib) capsules for the treatment of adult patients with...
Calculated Tumor Area Has Prognostic Value for Melanoma drugs
July 02, 2019
Calculated Tumor Area Has Prognostic Value for Melanoma.
Childhood Brain Tumor Survivors Face More Struggles drugs
June 26, 2019
Childhood Brain Tumor Survivors Face More Struggles.
Cristal Therapeutics to Present Data at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting on Lead Clinical Candidate CPC634 in Patients With Solid Tumors b3cnewswire
May 20, 2019
Florence Atrafi, MD, a clinical investigator on the phase 1 NAPOLY study, has received a prestigious ASCO Merit Award in recognition of her abstract that highlights important research findings.
Comprehensive tumor profiling promises new therapeutic options for patients with advanced cancer worldpharmanews
May 05, 2019
Comprehensive tumor profiling promises new therapeutic options for patients with advanced cancer.
BioAtla & BeiGene Enter Development Pact contractpharma
April 15, 2019
Agreement also covers the manufacturing and commercialization of BioAtla’s investigational CAB CTLA-4 antibody (BA3071).

Previous page 1 2 3 4 5 6 7 Next page